Praxis Precision Medicines
PRAX
103 hedge funds and large institutions have $108M invested in Praxis Precision Medicines in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 26 increasing their positions, 40 reducing their positions, and 23 closing their positions.
13% more capital invested
Capital invested by funds: $95.6M → $108M (+$12.2M)
0.26% more ownership
Funds ownership: 6.16% → 6.43% (+0.26%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less funds holding
Funds holding: 108 → 103 (-5)
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
35% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$3.81M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$3.53M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$3.08M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$1.66M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVA
Vida Ventures Advisors
Boston,
Massachusetts
|
-$3.06M |
| 2 |
Millennium Management
New York
|
-$1.69M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$1.42M |
| 4 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
-$1.06M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$926K |
PRAX Hedge Fund Activity: Q4 2022 in Review
103 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q4 2022, worth a combined $108M — up 13% from $95.6M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of PRAX and 18 opened new positions — a net loss of 5 holders — while 40 trimmed existing stakes and 26 added.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $3.81M. The largest seller was Vida Ventures Advisors, cutting an estimated $3.06M.
- 103 institutional investors held Praxis Precision Medicines (PRAX) as of Q4 2022, down from 108 in Q3 2022.
- Funds reported $108M of Praxis Precision Medicines stock for Q4 2022, up 13% quarter-over-quarter.
- 18 funds opened new Praxis Precision Medicines positions in Q4 2022 and 23 closed out, a net change of -5 holders.
- The largest Praxis Precision Medicines buyer in Q4 2022 was Baker Bros. Advisors, an estimated $3.81M added.
- The largest Praxis Precision Medicines seller in Q4 2022 was Vida Ventures Advisors, an estimated $3.06M sold.
Based on aggregated 13F filings for Q4 2022.